EU-funded EU4Monitoring Drugs holds advisory committee second meeting

November 25, 2020
Share on

Representatives of candidate, potential candidate and neighbouring countries of the EU are joining members of the EMCDDA’s Reitox network this week (23–27 November) for the agency’s ninth Reitox week. The purpose of this annual event is to broaden the scope of the regular Heads of national focal point (NFP) meetings, underline the usefulness of the EU drug monitoring model; add impetus to the agency’s technical cooperation with partners outside the EU and learn from each other’s experience.

The 2020 Reitox week, taking place for the first time virtually, unites some 50 countries, including: 29 NFPs (EU 27, Turkey and Norway); six partners of the Western Balkans (beneficiaries of the European Instrument for Pre-Accession Assistance/IPA7); 14 European Neighbourhood Policy (ENP) countries participating under the EU4Monitoring Drugs project (EU4MD); Switzerland and Russia.

The week encompasses four events. One of them is the Second meeting of the EU4MD advisory committee which kicked off the week. This session included project progress reports as well as updates from the partner countries, institutions and organisations.

The three-year EU-funded project EU4Monitoring Drugs – launched by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in January 2019 — supports national and regional readiness in the ENP area to identify and respond to drug-related health and security threats.

 

Read more

Press release

EU4Monitoring Drugs webpage

Countries covered:

  • Algeria
  • Egypt
  • Israel
  • Jordan
  • Lebanon
  • Libya
  • Morocco
  • Palestine *
  • Tunisia